FDA approves BMS's Opdivo for advanced melanoma

FDA granted accelerated approval to Opdivo nivolumab from Bristol Myers-Squibb Co. (NYSE:BMY) to treat unresectable or metastatic melanoma in patients previously treated with

Read the full 234 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE